Geode Capital Management
RGC icon

Geode Capital Management’s Regencell Bioscience RGC Stock Holding History

Geode Capital Management’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6M Buy
415,569
+2,487
+0.6% +$70.4K ﹤0.01% 2348
2025
Q4 		$8.67M Sell
413,082
-6,888
-2% -$112K ﹤0.01% 2479
2025
Q3 		$6.49M Buy
419,970
+28,904
+7% +$415K ﹤0.01% 2651
2025
Q2 		$6.66M Buy
391,066
+132,058
+51% +$1.61M ﹤0.01% 2584
2025
Q1 		$217K Buy
+259,008
New +$71.5K ﹤0.01% 3821
2022
Q4 		– Sell
-259,008
Closed -$216K – 4925
2022
Q3 		$216K Hold
259,008
– – ﹤0.01% 4170
2022
Q2 		$238K Buy
+259,008
New +$195K ﹤0.01% 4160
2022
Q1 		– Sell
-259,008
Closed -$224K – 5013
2021
Q4 		$224K Buy
+259,008
New +$157K ﹤0.01% 4422

Other funds holding RGC

MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Geode Capital Management's RGC Position: Q1 2026 in Review

Geode Capital Management increased its Regencell Bioscience (RGC) stake by 0.6% in Q1 2026, buying an estimated $70.4K and bringing the position to 415,569 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2348.

Geode Capital Management first reported a position in RGC in Q4 2021 and has held it in 8 quarters since. 31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • Geode Capital Management held 415,569 shares of Regencell Bioscience worth $10.6M as of Q1 2026.
  • Geode Capital Management bought 2,487 Regencell Bioscience shares in Q1 2026, an estimated $70.4K.
  • Regencell Bioscience made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2348 holding.
  • Geode Capital Management first reported a position in Regencell Bioscience in Q4 2021 and has held it in 8 quarters since.
  • 31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.